{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T20:57:15Z","timestamp":1781125035294,"version":"3.54.1"},"reference-count":65,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am Soc Clin Oncol Educ Book"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Advances in molecular and genomic techniques have significantly improved our understanding of pediatric brain tumors and enabled the development of targeted therapies directed at specific genetic alterations. The emergence of these therapies is reshaping the management of pediatric brain tumors, offering the potential for more effective and personalized treatment strategies, with reduced toxicity and improved clinical outcomes. This paradigm shift in pediatric neuro-oncology is still at an early stage but is expected to lead to substantial changes in clinical practice in the coming years. Clinical research has already resulted in the approval of several targeted agents, particularly for tumors driven by alterations in the MAP kinase pathway. These successes underscore the importance of integrating molecular diagnostics into routine care. This review summarizes the clinical development and regulatory approval of targeted therapies in pediatric brain tumors. It also addresses key challenges in the design and conduct of clinical trials in this unique population, including small patient numbers. In addition, several critical questions remain unresolved, such as the optimal duration of therapy, the durability of responses, mechanisms of resistance, and the long-term effects of these treatments in children. Finally, this review discusses issues related to access and equity, particularly the availability of these often-costly therapies in low- and middle-income countries, which remains a significant barrier to their global implementation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/edbk-26-517598","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T19:59:10Z","timestamp":1781121550000},"source":"Crossref","is-referenced-by-count":0,"title":["Approved Targeted Treatments for Pediatric Brain Tumors"],"prefix":"10.1200","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6832-6539","authenticated-orcid":true,"given":"Eric","family":"Bouffet","sequence":"first","affiliation":[{"name":"Neuro-Oncology Section, The Hospital for Sick Children, University of Toronto, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Neal","family":"Franz","sequence":"additional","affiliation":[{"name":"Division of Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH"},{"name":"Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Arrillaga-Romany","sequence":"additional","affiliation":[{"name":"Department of Neurology, Center for Neuro-Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Jalali","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hematology, BMT and Cellular Therapy, Apollo Proton Cancer Centre, Chennai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1177\/0883073815587944"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441401"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-1541-5_20"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0968-0004(93)90069-Y"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1469-1809.2003.00012.x"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2006.05.018"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20784"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001671"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/pd.6640"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2021.09.014"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nox141"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30277-3"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-022-00888-9"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae119"},{"key":"e_1_3_2_16_2","first-page":"iv129","article-title":"LGG-53. Results from the phase 1 and phase 1 expansion cohorts of SJ901: A phase 1\/2 trial of single-agent mirdametinib (PD-0325901) in children, adolescents, and young adults with low-grade glioma","volume":"26","author":"Robinson GW","year":"2024","unstructured":"Robinson GW, Vinitsky A, Bag AK, et al: LGG-53. Results from the phase 1 and phase 1 expansion cohorts of SJ901: A phase 1\/2 trial of single-agent mirdametinib (PD-0325901) in children, adolescents, and young adults with low-grade glioma. Neurooncology 26(suppl 4):iv129-iv130, 2024","journal-title":"Neurooncology"},{"key":"e_1_3_2_17_2","first-page":"i191","article-title":"LTBK-04. Late breaking abstract: MEK162 (binimetinib) in children with progressive or recurrent low-grade glioma: A multi-institutional phase II and target validation study","volume":"24","author":"Robison N","year":"2022","unstructured":"Robison N, Pauly J, Malvar J, et al: LTBK-04. Late breaking abstract: MEK162 (binimetinib) in children with progressive or recurrent low-grade glioma: A multi-institutional phase II and target validation study. Neurooncology 24:i191-i192, 2022 (suppl 1)","journal-title":"Neurooncology"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2177"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01000"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303815"},{"key":"e_1_3_2_21_2","unstructured":"Reference deleted"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02668-y"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00558"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac096"},{"key":"e_1_3_2_25_2","unstructured":"Reference deleted"},{"key":"e_1_3_2_26_2","article-title":"Analysis of NTRK alterations in pan-cancer adult and pediatric malignancies: Implications for NTRK-targeted therapeutics","author":"Okamura R","unstructured":"Okamura R, Boichard A, Kato S, et al: Analysis of NTRK alterations in pan-cancer adult and pediatric malignancies: Implications for NTRK-targeted therapeutics. JCO Precis Oncol 10.1200\/PO.18.00183","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-018-0118-3"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12187-5"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab274"},{"key":"e_1_3_2_30_2","first-page":"iv84","article-title":"HGG-02. Long-term efficacy and safety of larotrectinib in pediatric patients with TRK fusion primary central nervous system (CNS) tumors: An updated analysis","volume":"26","author":"Perreault S","year":"2024","unstructured":"Perreault S, Doz F, Deyell RJ, et al: HGG-02. Long-term efficacy and safety of larotrectinib in pediatric patients with TRK fusion primary central nervous system (CNS) tumors: An updated analysis. Neurooncology 26(suppl 4):iv84-iv85, 2024","journal-title":"Neurooncology"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115308"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2101264"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac026"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30312"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30410"},{"key":"e_1_3_2_36_2","article-title":"Debio1347, an oral FGFR inhibitor: Results from a single-center study in pediatric patients with recurrent or refractory FGFR-altered gliomas","author":"Farouk SS","unstructured":"Farouk SS, Gilheeney SW, Bale TA, et al: Debio1347, an oral FGFR inhibitor: Results from a single-center study in pediatric patients with recurrent or refractory FGFR-altered gliomas. JCO Precis Oncol 10.1200\/PO.20.00444","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.2042"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2017.04.008"},{"key":"e_1_3_2_39_2","article-title":"MEK inhibition in a pilocytic astrocytoma with a rare KRAS Q61R mutation in a young adult patient: A case report","author":"Roberto K","unstructured":"Roberto K, Keith J, Levine A, et al: MEK inhibition in a pilocytic astrocytoma with a rare KRAS Q61R mutation in a young adult patient: A case report. JCO Precis Oncol 10.1200\/PO.24.00174","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_2_40_2","unstructured":"U.S. Food and Drug Administration: FDA grants accelerated approval to dordaviprone for diffuse midline glioma. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-dordaviprone-diffuse-midline-glioma"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1124\/molpharm.121.000336"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.9b00222"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0131"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01134"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01059"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae031"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304194"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-00962-x"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.1591"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nox109"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.20619"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noad191"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nov017"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac151"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.10040"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.13329"},{"key":"e_1_3_2_57_2","first-page":"1","article-title":"Drug development in low- and middle-income countries: Opportunity or exploitation?","volume":"42","author":"Jalali R","year":"2022","unstructured":"Jalali R, Nogueira-Rodrigues A, Das A, et al: Drug development in low- and middle-income countries: Opportunity or exploitation? Am Soc Clin Oncol Educ Book 42:1-8, 2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26879"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2022.100861"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.6552"},{"key":"e_1_3_2_61_2","volume-title":"ZRC-3197 (Nivolumab Biosimilar) Clinical Development and Regulatory Information","author":"Zydus Lifesciences Ltd","unstructured":"Zydus Lifesciences Ltd: ZRC-3197 (Nivolumab Biosimilar) Clinical Development and Regulatory Information. Ahmedabad (India), Zydus Lifesciences. https:\/\/www.zyduslife.com"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa052"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.114.058339"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.112.192195"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-024-04899-6"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14112683"}],"container-title":["American Society of Clinical Oncology Educational Book"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/EDBK-26-517598","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T19:59:13Z","timestamp":1781121553000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/EDBK-26-517598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1200\/EDBK-26-517598"],"URL":"https:\/\/doi.org\/10.1200\/edbk-26-517598","relation":{},"ISSN":["1548-8748","1548-8756"],"issn-type":[{"value":"1548-8748","type":"print"},{"value":"1548-8756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"article-number":"e517598"}}